David Giegel, Ph.D.
Founder, CSO and President, TissueNetix, Inc

Dr. Giegel has twenty years of experience in drug discovery at large pharmaceutical companies and small biotechnology companies.  Prior to founding TissueNetix, he was Senior Director of Molecular Sciences at Celgene, where he was responsible for overseeing the in vitro drug discovery efforts of the company's San Diego research site.  Dr. Giegel has also held management positions at MitoKor, Pfizer and Parke-Davis.  Dr. Giegel received his M.S. and Ph.D. (Biological Chemistry) from the University of Michigan and a B.S. degree (Chemistry) from Miami University (Ohio).

 Sandra Hara

Sandra Hara
Owner, Hara CPA Professional Services, Inc.
Chief Financial Officer & Member, Board of Directors, TissueNetix, Inc 

Ms. Hara’s experience includes more than fifteen years in public accounting and tax, and another fifteen years in the private sector working with a wide range of companies from start-ups to companies with revenues of $500 million.  She has held positions of Controller, CFO and COO, giving her the wide range of knowledge to understand every business’ needs.  Ms. Hara’s career in accounting and finance includes expertise in creating accounting policies and procedures as well as providing direction in all phases of accounting department management and operations.  In addition, she has worked closely with a variety of industries including retail, construction, high-tech, entertainment, legal, restaurant, telecommunications, manufacturing and non-profit organizations. 

 

Lewis Shuster, M.B. A.
Chief Executive Officer, Shuster Capital
Founder & Executive Chairman, TissueNetix, Inc 

In 2002, Mr. Shuster founded Shuster Capital, a strategic and operating advisor to, and angel investor in, life science companies, and has served as its chief executive officer since.  Prior to founding Shuster Capital, he served as chief executive officer of Kemia, Inc., a drug discovery and development company.  Mr. Shuster has had senior leadership positions at Invitrogen, Pharmacopeia, Inc. and Human Genome Sciences (where he was the first employee).  He currently is a member the board of directors at several companies in the life sciences field.  Mr. Shuster received a B.A. in Economics from Swarthmore College and an M.B.A. from Stanford University.

 Roberta Gottlieb

Roberta Gottlieb, M.D.
Director of Molecular Cardiobiology, Cedars-Sinai Medical Center
Founder, TissueNetix, Inc 

Dr. Gottlieb has been conducting NIH-funded cardiovascular research for the past 20 years.  Prior to her current position, she was on faculty at The Scripps Research Institute.  From Scripps, she was recruited by San Diego State University to become the first Director of the Donald P. Shiley BioScience Center.  The work in her lab has led to the discovery of cardioprotective agents and the elucidation of their novel mechanism of action.  Dr. Gottlieb’s expertise in cardioprotection and autophagy is recognized on a national and international level.  She is also an entrepreneur, having started a biotechnology company called Radical Therapeutix with the goal of developing cardioprotective drugs.  Dr. Gottlieb received her B.S. and M.D. degrees from Johns Hopkins University.

 Dave Webb

David Webb, Ph.D.
Chairman, Sorrento Therapeutics
Advisor, TissueNetix, Inc

In addition to his role as Chairman of Sorrento Therapeutics, Dr. Webb is Adjunct Professor in Molecular Biology at the Scripps Research Institute.  Prior to this he was Vice President of Research at Celgene, where his division was responsible for placing 6 drugs into clinical development in the areas of oncology and inflammatory diseases.  Dr. Webb has had senior leadership roles at several companies prior to joining Celgene, including Syrrx, OSI Pharmaceuticals, Cadus Pharmaceutical Corporation and Syntex.  He earned his Ph.D. in Microbiology/Immunology at Rutgers, The State University of New Jersey-New Brunswick, and a BA and MA in Biology from California State University-Fullerton.

Burt De Mill

Burt De Mill
BDM Consulting
Advisor, TissueNetix, Inc

Mr. De Mill has over 20 years of management experience in the life science tools and clinical diagnostics markets. He most recently served as Chief Commercial Officer at Lineagen, where he managed the successful launch of FirstStep Dx, an array based genetic test for autism and developmental delay. Burt served as Senior Vice President, Sales & Marketing with Genoptix, where he grew revenues from $4M to $184M, and market share from <1% to 7% in less than five years. Mr. De Mill was formerly Vice President, U.S. Commercial Operations with Invitrogen Corporation (Life Technologies), and Vice President, Separations North America with Amersham Biosciences (GE Health).  Mr. De Mill earned a Bachelor of Science in Microbiology from the University of Maryland, College Park.

Go to top